Latest Breaking News On - Cellular biomedicine group - Page 1 : vimarsana.com

DelveInsight Business Research, LLP: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES

The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22

CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032)

/PRNewswire/ -- DelveInsight's CAR T-Cell Therapy Market Insights report includes a comprehensive understanding of current treatment practices, emerging CAR...

DelveInsight Business Research, LLP: CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032)

Iovance: Approval For Solid Tumor Targeting TIL Therapy Likely, Outlook Promising (IOVA)

PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline Insights | 30+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |

Navigating the Evolving Market Dynamics of Bone Sarcoma: A Comprehensive Analysis of Osteosarcoma, Ewing Sarcoma, and Chondrosarcoma

/PRNewswire/ -- Bone sarcoma is a rare and aggressive form of cancer that originates in the bone tissue. It poses significant challenges during its treatment...

DelveInsight Business Research, LLP: Navigating the Evolving Market Dynamics of Bone Sarcoma: A Comprehensive Analysis of Osteosarcoma, Ewing Sarcoma, and Chondrosarcoma

Global CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key Players

/PRNewswire/ -- The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. CD19 targeting...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in...